Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

TFF Pharmaceuticals, Inc. TFFP

Healthcare — Biotechnology
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

TFF Pharmaceuticals, Inc. (TFFP) Business Profile

Company Overview

TFF Pharmaceuticals, Inc. (TFFP) is a clinical-stage biopharmaceutical company headquartered in Austin, Texas. The company was founded in 2018 with the mission of revolutionizing drug delivery through its proprietary Thin Film Freezing (TFF) technology. TFF Pharmaceuticals focuses on developing innovative therapies that address unmet medical needs, particularly in the areas of respiratory and infectious diseases. The company is led by a team of seasoned professionals with extensive experience in the pharmaceutical and biotechnology industries. Key leadership includes Glenn Mattes, who serves as the President and Chief Executive Officer, and Kirk Coleman, the Chief Financial Officer. Their leadership has been instrumental in driving the company’s growth and advancing its pipeline of drug candidates.

Core Business Segments

Thin Film Freezing Technology

TFF Pharmaceuticals’ core offering is its proprietary Thin Film Freezing (TFF) technology. This platform enables the transformation of poorly water-soluble drugs into dry powder formulations, improving their solubility, stability, and bioavailability. The technology is particularly suited for inhalation therapies, making it a game-changer in the treatment of respiratory diseases.

Drug Development Pipeline

TFF Pharmaceuticals has a robust pipeline of drug candidates targeting various therapeutic areas:

  • Voriconazole Inhalation Powder: Designed for the treatment of invasive pulmonary aspergillosis, a severe fungal infection.
  • Tacrolimus Inhalation Powder: Aimed at preventing organ rejection in lung transplant patients.
  • Niclosamide Inhalation Powder: Being developed as a potential treatment for COVID-19 and other viral infections.

Licensing and Partnerships

In addition to its internal pipeline, TFF Pharmaceuticals collaborates with pharmaceutical companies to apply its TFF technology to their drug candidates. This segment generates revenue through licensing agreements, milestone payments, and royalties.

Business Model

TFF Pharmaceuticals operates on a dual business model that combines internal drug development with external partnerships. The company invests in the research and development of its proprietary drug candidates while also licensing its TFF technology to other pharmaceutical companies. Revenue is generated through:

  • Product Sales: Once approved, the company’s drug candidates will generate revenue through direct sales.
  • Licensing Agreements: TFF licenses its technology to other companies, earning upfront payments, milestones, and royalties.
  • Collaborations: Joint development agreements with other pharmaceutical firms provide additional revenue streams.

This hybrid model allows TFF Pharmaceuticals to diversify its revenue sources while leveraging its core technology.

Strategic Direction

TFF Pharmaceuticals is focused on expanding its pipeline and commercializing its drug candidates. Key strategic priorities include:

  • Advancing Clinical Trials: The company is committed to progressing its lead candidates, such as Voriconazole and Tacrolimus, through clinical trials.
  • Expanding Partnerships: TFF aims to establish more collaborations with pharmaceutical companies to broaden the application of its TFF technology.
  • Sustainability Goals: The company is exploring eco-friendly manufacturing processes and aims to minimize its environmental footprint.
  • New Product Categories: TFF is investigating the potential of its technology in areas such as oncology and central nervous system disorders.

Competitive Landscape

TFF Pharmaceuticals operates in a competitive biopharmaceutical market. Key competitors include:

  • Pulmatrix, Inc.: Focused on inhalation therapies for respiratory diseases.
  • Insmed Incorporated: Specializes in therapies for rare diseases, including respiratory conditions.
  • Vertex Pharmaceuticals: A leader in cystic fibrosis treatments.
  • Aridis Pharmaceuticals: Develops therapies for infectious diseases.

TFF differentiates itself through its proprietary TFF technology, which offers unique advantages in drug formulation and delivery.

Risk Factors

TFF Pharmaceuticals faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: The approval process for new drugs is lengthy and uncertain.
  • Market Dependence: The company’s success is heavily reliant on the commercialization of its lead candidates.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers poses a risk.
  • Competition: Intense competition from established players and new entrants could affect market share.
  • Financial Risks: As a clinical-stage company, TFF relies on external funding and has yet to achieve profitability.

Recent Developments

TFF Pharmaceuticals has made significant strides in recent months:

  • Clinical Trial Progress: The company announced positive interim results from Phase 2 trials of its Voriconazole Inhalation Powder.
  • New Partnerships: TFF entered into a collaboration with a leading pharmaceutical company to apply its TFF technology to a new drug candidate.
  • COVID-19 Research: The development of Niclosamide Inhalation Powder as a potential COVID-19 treatment has gained attention.
  • Global Developments: The ongoing pandemic has highlighted the importance of innovative drug delivery systems, boosting interest in TFF’s technology.

Investment Considerations

Strengths

  • Innovative Technology: TFF’s proprietary platform offers a competitive edge.
  • Strong Pipeline: A diverse range of drug candidates targeting high-need areas.
  • Experienced Leadership: A seasoned management team with a proven track record.
  • Partnership Opportunities: Licensing agreements provide additional revenue streams.

Risks

  • Clinical and Regulatory Uncertainty: Drug development is inherently risky.
  • Financial Dependence: Reliance on external funding poses a challenge.
  • Market Competition: Intense competition from established players.

Conclusion

TFF Pharmaceuticals is well-positioned to become a leader in the biopharmaceutical industry, thanks to its innovative Thin Film Freezing technology and strong pipeline of drug candidates. While the company faces challenges typical of clinical-stage firms, its strategic direction and partnerships provide a solid foundation for future growth. Investors should weigh the company’s strengths against its risks to make informed decisions. With its focus on addressing unmet medical needs, TFF Pharmaceuticals has the potential to make a significant impact in the healthcare sector.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us